human monocytes Search Results


95
ATCC a baumannii atcc 19606
A Baumannii Atcc 19606, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+monocytes/Monocytes+derived+from%3B+DYS0100+Induced%3B+Pluripotent+Stem+Cell%3B+Human/10__1021_slash_acs__jmedchem__1c01033-239-19-21
Average 95 stars, based on 1 article reviews
a baumannii atcc 19606 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

96
Miltenyi Biotec classical monocyte isolation kit
Classical Monocyte Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+monocytes/Classical+Monocyte+Isolation+Kit%2C+human/pm36263044-157-13-17
Average 96 stars, based on 1 article reviews
classical monocyte isolation kit - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

94
Elabscience Biotechnology e el h0102c
E El H0102c, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+monocytes/Human+MCP-1+(Monocyte+Chemotactic+Protein+1)+ELISA+Kit/pmc08130406-114-27-25
Average 94 stars, based on 1 article reviews
e el h0102c - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

91
Revvity monocyte chemoattractant protein 1 mcp 1 elisa kits
Monocyte Chemoattractant Protein 1 Mcp 1 Elisa Kits, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+monocytes/Monocyte+Chemoattractant+Protein-1+(human)+AlphaLISA+Detection+Kit%2C+500+Assay+Points/pmc05750214-234-4-13
Average 91 stars, based on 1 article reviews
monocyte chemoattractant protein 1 mcp 1 elisa kits - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier

96
Miltenyi Biotec pan monocyte isolation kit
Pan Monocyte Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+monocytes/Pan+Monocyte+Isolation+Kit%2C+human/pm29017604-61-10-14
Average 96 stars, based on 1 article reviews
pan monocyte isolation kit - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

94
Beijing Solarbio Science peripheral blood monocyte isolation solution kit
Figure 7. DCD is beneficial to AIS recovery and DCD-containing BM-MSC-derived migrasome effectively promotes phagocytosis of macrophages. A– G) <t>Peripheral</t> blood of AIS patients (acute phase, 0–3d after disease onset, n = 16) and healthy controls (HC, n = 8) were collected. (A) Plasma DCD concentration was assessed with ELISA. *p < 0.05, compared with HC by Student’s t-test (mean ± standard deviation). (B) Correlation of clinic parameters and plasma DCD concentration was assessed with Spearman correlation analysis and Point-biserial correlations. *p < 0.05. DM, diabetes mellitus, CHD, coronary heart disease. (C) Representative images of the magnetic resonance diffusion weighted imaging (MR-DWI) of AIS patients with low plasma DCD concentration (DCD ≤3.33 ng ml−1) or high plasma DCD concentration (DCD > 3.33 ng ml−1). (D) Association between plasma DCD concentration with infarct scale was estimated with Spearman correlation analysis. (E) Association between plasma DCD concentration with delta NIHSS (NIHSS at 7d minus NIHSS at 1d) was estimated with Spearman correlation analysis. (F) Representative images of the chest Computed Tomography (CT) of AIS patients with low plasma DCD concentration (DCD ≤3.39 ng ml−1, median of the cohort) or high plasma DCD concentration (DCD > 3.39 ng ml−1, median of the cohort). (G) Pie charts showing the occurrence of post-stroke pneumonia in AIS patients with low and high plasma DCD concentrations. H) DCD (1 ng ml−1), PBS-migrasomes (PBS-M, 50 μg ml−1) or E. Coli-migrasomes (E. Coli-M, 50 μg ml−1) labeled with Dil (red) were treated to BMDM (15 min). Immunostaining of WGA (green) and DCD (withe) in migrasome-treated BMDM was performed. Experiments were repeated for three times. I,J) BMDM were first pre-stimulated with DCD (1 ng ml−1), PBS-M (50 μg ml−1), or E. Coli-M (50 μg ml−1) for overnight then treated with E. Coli (E. Coli : BMDM = 20:1, 1 h). Phagocytic efficiency of BMDM to GFP expressing E. Coli was assessed with flow cytometry (I) and immunostaining (J). Experiments were repeated three times. **p < 0.01, compared with PBS-treated group by one-way ANOVA (mean ± standard deviation).
Peripheral Blood Monocyte Isolation Solution Kit, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+monocytes/Human+Peripheral+Blood+Monocyte+Isolation+Solution+Kit/pm37246283-348-21-27
Average 94 stars, based on 1 article reviews
peripheral blood monocyte isolation solution kit - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

99
ATCC monocytic leukemia
Figure 7. DCD is beneficial to AIS recovery and DCD-containing BM-MSC-derived migrasome effectively promotes phagocytosis of macrophages. A– G) <t>Peripheral</t> blood of AIS patients (acute phase, 0–3d after disease onset, n = 16) and healthy controls (HC, n = 8) were collected. (A) Plasma DCD concentration was assessed with ELISA. *p < 0.05, compared with HC by Student’s t-test (mean ± standard deviation). (B) Correlation of clinic parameters and plasma DCD concentration was assessed with Spearman correlation analysis and Point-biserial correlations. *p < 0.05. DM, diabetes mellitus, CHD, coronary heart disease. (C) Representative images of the magnetic resonance diffusion weighted imaging (MR-DWI) of AIS patients with low plasma DCD concentration (DCD ≤3.33 ng ml−1) or high plasma DCD concentration (DCD > 3.33 ng ml−1). (D) Association between plasma DCD concentration with infarct scale was estimated with Spearman correlation analysis. (E) Association between plasma DCD concentration with delta NIHSS (NIHSS at 7d minus NIHSS at 1d) was estimated with Spearman correlation analysis. (F) Representative images of the chest Computed Tomography (CT) of AIS patients with low plasma DCD concentration (DCD ≤3.39 ng ml−1, median of the cohort) or high plasma DCD concentration (DCD > 3.39 ng ml−1, median of the cohort). (G) Pie charts showing the occurrence of post-stroke pneumonia in AIS patients with low and high plasma DCD concentrations. H) DCD (1 ng ml−1), PBS-migrasomes (PBS-M, 50 μg ml−1) or E. Coli-migrasomes (E. Coli-M, 50 μg ml−1) labeled with Dil (red) were treated to BMDM (15 min). Immunostaining of WGA (green) and DCD (withe) in migrasome-treated BMDM was performed. Experiments were repeated for three times. I,J) BMDM were first pre-stimulated with DCD (1 ng ml−1), PBS-M (50 μg ml−1), or E. Coli-M (50 μg ml−1) for overnight then treated with E. Coli (E. Coli : BMDM = 20:1, 1 h). Phagocytic efficiency of BMDM to GFP expressing E. Coli was assessed with flow cytometry (I) and immunostaining (J). Experiments were repeated three times. **p < 0.01, compared with PBS-treated group by one-way ANOVA (mean ± standard deviation).
Monocytic Leukemia, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+monocytes/THP-1%3B+Acute+Monocytic+Leukemia%3B+Human/pmc12980868-41-14-17
Average 99 stars, based on 1 article reviews
monocytic leukemia - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

94
ATCC human monocytic leukemia cells
Figure 7. DCD is beneficial to AIS recovery and DCD-containing BM-MSC-derived migrasome effectively promotes phagocytosis of macrophages. A– G) <t>Peripheral</t> blood of AIS patients (acute phase, 0–3d after disease onset, n = 16) and healthy controls (HC, n = 8) were collected. (A) Plasma DCD concentration was assessed with ELISA. *p < 0.05, compared with HC by Student’s t-test (mean ± standard deviation). (B) Correlation of clinic parameters and plasma DCD concentration was assessed with Spearman correlation analysis and Point-biserial correlations. *p < 0.05. DM, diabetes mellitus, CHD, coronary heart disease. (C) Representative images of the magnetic resonance diffusion weighted imaging (MR-DWI) of AIS patients with low plasma DCD concentration (DCD ≤3.33 ng ml−1) or high plasma DCD concentration (DCD > 3.33 ng ml−1). (D) Association between plasma DCD concentration with infarct scale was estimated with Spearman correlation analysis. (E) Association between plasma DCD concentration with delta NIHSS (NIHSS at 7d minus NIHSS at 1d) was estimated with Spearman correlation analysis. (F) Representative images of the chest Computed Tomography (CT) of AIS patients with low plasma DCD concentration (DCD ≤3.39 ng ml−1, median of the cohort) or high plasma DCD concentration (DCD > 3.39 ng ml−1, median of the cohort). (G) Pie charts showing the occurrence of post-stroke pneumonia in AIS patients with low and high plasma DCD concentrations. H) DCD (1 ng ml−1), PBS-migrasomes (PBS-M, 50 μg ml−1) or E. Coli-migrasomes (E. Coli-M, 50 μg ml−1) labeled with Dil (red) were treated to BMDM (15 min). Immunostaining of WGA (green) and DCD (withe) in migrasome-treated BMDM was performed. Experiments were repeated for three times. I,J) BMDM were first pre-stimulated with DCD (1 ng ml−1), PBS-M (50 μg ml−1), or E. Coli-M (50 μg ml−1) for overnight then treated with E. Coli (E. Coli : BMDM = 20:1, 1 h). Phagocytic efficiency of BMDM to GFP expressing E. Coli was assessed with flow cytometry (I) and immunostaining (J). Experiments were repeated three times. **p < 0.01, compared with PBS-treated group by one-way ANOVA (mean ± standard deviation).
Human Monocytic Leukemia Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+monocytes/Human+monocytic+leukemia+cells+MC-1010/pm22863916-35-2-10
Average 94 stars, based on 1 article reviews
human monocytic leukemia cells - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

99
ATCC peripheral blood cells
Figure 7. DCD is beneficial to AIS recovery and DCD-containing BM-MSC-derived migrasome effectively promotes phagocytosis of macrophages. A– G) <t>Peripheral</t> blood of AIS patients (acute phase, 0–3d after disease onset, n = 16) and healthy controls (HC, n = 8) were collected. (A) Plasma DCD concentration was assessed with ELISA. *p < 0.05, compared with HC by Student’s t-test (mean ± standard deviation). (B) Correlation of clinic parameters and plasma DCD concentration was assessed with Spearman correlation analysis and Point-biserial correlations. *p < 0.05. DM, diabetes mellitus, CHD, coronary heart disease. (C) Representative images of the magnetic resonance diffusion weighted imaging (MR-DWI) of AIS patients with low plasma DCD concentration (DCD ≤3.33 ng ml−1) or high plasma DCD concentration (DCD > 3.33 ng ml−1). (D) Association between plasma DCD concentration with infarct scale was estimated with Spearman correlation analysis. (E) Association between plasma DCD concentration with delta NIHSS (NIHSS at 7d minus NIHSS at 1d) was estimated with Spearman correlation analysis. (F) Representative images of the chest Computed Tomography (CT) of AIS patients with low plasma DCD concentration (DCD ≤3.39 ng ml−1, median of the cohort) or high plasma DCD concentration (DCD > 3.39 ng ml−1, median of the cohort). (G) Pie charts showing the occurrence of post-stroke pneumonia in AIS patients with low and high plasma DCD concentrations. H) DCD (1 ng ml−1), PBS-migrasomes (PBS-M, 50 μg ml−1) or E. Coli-migrasomes (E. Coli-M, 50 μg ml−1) labeled with Dil (red) were treated to BMDM (15 min). Immunostaining of WGA (green) and DCD (withe) in migrasome-treated BMDM was performed. Experiments were repeated for three times. I,J) BMDM were first pre-stimulated with DCD (1 ng ml−1), PBS-M (50 μg ml−1), or E. Coli-M (50 μg ml−1) for overnight then treated with E. Coli (E. Coli : BMDM = 20:1, 1 h). Phagocytic efficiency of BMDM to GFP expressing E. Coli was assessed with flow cytometry (I) and immunostaining (J). Experiments were repeated three times. **p < 0.01, compared with PBS-treated group by one-way ANOVA (mean ± standard deviation).
Peripheral Blood Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+monocytes/Primary+Peripheral+Blood+CD14%2B+Monocytes%2C+Normal%2C+Human/pmc05305699-51-1-4
Average 99 stars, based on 1 article reviews
peripheral blood cells - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

95
Bio X Cell human pd 1 antibodies
Figure 7. DCD is beneficial to AIS recovery and DCD-containing BM-MSC-derived migrasome effectively promotes phagocytosis of macrophages. A– G) <t>Peripheral</t> blood of AIS patients (acute phase, 0–3d after disease onset, n = 16) and healthy controls (HC, n = 8) were collected. (A) Plasma DCD concentration was assessed with ELISA. *p < 0.05, compared with HC by Student’s t-test (mean ± standard deviation). (B) Correlation of clinic parameters and plasma DCD concentration was assessed with Spearman correlation analysis and Point-biserial correlations. *p < 0.05. DM, diabetes mellitus, CHD, coronary heart disease. (C) Representative images of the magnetic resonance diffusion weighted imaging (MR-DWI) of AIS patients with low plasma DCD concentration (DCD ≤3.33 ng ml−1) or high plasma DCD concentration (DCD > 3.33 ng ml−1). (D) Association between plasma DCD concentration with infarct scale was estimated with Spearman correlation analysis. (E) Association between plasma DCD concentration with delta NIHSS (NIHSS at 7d minus NIHSS at 1d) was estimated with Spearman correlation analysis. (F) Representative images of the chest Computed Tomography (CT) of AIS patients with low plasma DCD concentration (DCD ≤3.39 ng ml−1, median of the cohort) or high plasma DCD concentration (DCD > 3.39 ng ml−1, median of the cohort). (G) Pie charts showing the occurrence of post-stroke pneumonia in AIS patients with low and high plasma DCD concentrations. H) DCD (1 ng ml−1), PBS-migrasomes (PBS-M, 50 μg ml−1) or E. Coli-migrasomes (E. Coli-M, 50 μg ml−1) labeled with Dil (red) were treated to BMDM (15 min). Immunostaining of WGA (green) and DCD (withe) in migrasome-treated BMDM was performed. Experiments were repeated for three times. I,J) BMDM were first pre-stimulated with DCD (1 ng ml−1), PBS-M (50 μg ml−1), or E. Coli-M (50 μg ml−1) for overnight then treated with E. Coli (E. Coli : BMDM = 20:1, 1 h). Phagocytic efficiency of BMDM to GFP expressing E. Coli was assessed with flow cytometry (I) and immunostaining (J). Experiments were repeated three times. **p < 0.01, compared with PBS-treated group by one-way ANOVA (mean ± standard deviation).
Human Pd 1 Antibodies, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+monocytes/Human+IL-8+Recombinant+Protein/pm39937158-303-2-8
Average 95 stars, based on 1 article reviews
human pd 1 antibodies - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

94
MedChemExpress cd14 pbmc cells
Figure 7. DCD is beneficial to AIS recovery and DCD-containing BM-MSC-derived migrasome effectively promotes phagocytosis of macrophages. A– G) <t>Peripheral</t> blood of AIS patients (acute phase, 0–3d after disease onset, n = 16) and healthy controls (HC, n = 8) were collected. (A) Plasma DCD concentration was assessed with ELISA. *p < 0.05, compared with HC by Student’s t-test (mean ± standard deviation). (B) Correlation of clinic parameters and plasma DCD concentration was assessed with Spearman correlation analysis and Point-biserial correlations. *p < 0.05. DM, diabetes mellitus, CHD, coronary heart disease. (C) Representative images of the magnetic resonance diffusion weighted imaging (MR-DWI) of AIS patients with low plasma DCD concentration (DCD ≤3.33 ng ml−1) or high plasma DCD concentration (DCD > 3.33 ng ml−1). (D) Association between plasma DCD concentration with infarct scale was estimated with Spearman correlation analysis. (E) Association between plasma DCD concentration with delta NIHSS (NIHSS at 7d minus NIHSS at 1d) was estimated with Spearman correlation analysis. (F) Representative images of the chest Computed Tomography (CT) of AIS patients with low plasma DCD concentration (DCD ≤3.39 ng ml−1, median of the cohort) or high plasma DCD concentration (DCD > 3.39 ng ml−1, median of the cohort). (G) Pie charts showing the occurrence of post-stroke pneumonia in AIS patients with low and high plasma DCD concentrations. H) DCD (1 ng ml−1), PBS-migrasomes (PBS-M, 50 μg ml−1) or E. Coli-migrasomes (E. Coli-M, 50 μg ml−1) labeled with Dil (red) were treated to BMDM (15 min). Immunostaining of WGA (green) and DCD (withe) in migrasome-treated BMDM was performed. Experiments were repeated for three times. I,J) BMDM were first pre-stimulated with DCD (1 ng ml−1), PBS-M (50 μg ml−1), or E. Coli-M (50 μg ml−1) for overnight then treated with E. Coli (E. Coli : BMDM = 20:1, 1 h). Phagocytic efficiency of BMDM to GFP expressing E. Coli was assessed with flow cytometry (I) and immunostaining (J). Experiments were repeated three times. **p < 0.01, compared with PBS-treated group by one-way ANOVA (mean ± standard deviation).
Cd14 Pbmc Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+monocytes/CD14%2C+Human/pmc12964385-121-1-26
Average 94 stars, based on 1 article reviews
cd14 pbmc cells - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
MedChemExpress mce standard
Figure 7. DCD is beneficial to AIS recovery and DCD-containing BM-MSC-derived migrasome effectively promotes phagocytosis of macrophages. A– G) <t>Peripheral</t> blood of AIS patients (acute phase, 0–3d after disease onset, n = 16) and healthy controls (HC, n = 8) were collected. (A) Plasma DCD concentration was assessed with ELISA. *p < 0.05, compared with HC by Student’s t-test (mean ± standard deviation). (B) Correlation of clinic parameters and plasma DCD concentration was assessed with Spearman correlation analysis and Point-biserial correlations. *p < 0.05. DM, diabetes mellitus, CHD, coronary heart disease. (C) Representative images of the magnetic resonance diffusion weighted imaging (MR-DWI) of AIS patients with low plasma DCD concentration (DCD ≤3.33 ng ml−1) or high plasma DCD concentration (DCD > 3.33 ng ml−1). (D) Association between plasma DCD concentration with infarct scale was estimated with Spearman correlation analysis. (E) Association between plasma DCD concentration with delta NIHSS (NIHSS at 7d minus NIHSS at 1d) was estimated with Spearman correlation analysis. (F) Representative images of the chest Computed Tomography (CT) of AIS patients with low plasma DCD concentration (DCD ≤3.39 ng ml−1, median of the cohort) or high plasma DCD concentration (DCD > 3.39 ng ml−1, median of the cohort). (G) Pie charts showing the occurrence of post-stroke pneumonia in AIS patients with low and high plasma DCD concentrations. H) DCD (1 ng ml−1), PBS-migrasomes (PBS-M, 50 μg ml−1) or E. Coli-migrasomes (E. Coli-M, 50 μg ml−1) labeled with Dil (red) were treated to BMDM (15 min). Immunostaining of WGA (green) and DCD (withe) in migrasome-treated BMDM was performed. Experiments were repeated for three times. I,J) BMDM were first pre-stimulated with DCD (1 ng ml−1), PBS-M (50 μg ml−1), or E. Coli-M (50 μg ml−1) for overnight then treated with E. Coli (E. Coli : BMDM = 20:1, 1 h). Phagocytic efficiency of BMDM to GFP expressing E. Coli was assessed with flow cytometry (I) and immunostaining (J). Experiments were repeated three times. **p < 0.01, compared with PBS-treated group by one-way ANOVA (mean ± standard deviation).
Mce Standard, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+monocytes/CXCL17%2C+Human/pmc10187107-39-10-10
Average 94 stars, based on 1 article reviews
mce standard - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results


Figure 7. DCD is beneficial to AIS recovery and DCD-containing BM-MSC-derived migrasome effectively promotes phagocytosis of macrophages. A– G) Peripheral blood of AIS patients (acute phase, 0–3d after disease onset, n = 16) and healthy controls (HC, n = 8) were collected. (A) Plasma DCD concentration was assessed with ELISA. *p < 0.05, compared with HC by Student’s t-test (mean ± standard deviation). (B) Correlation of clinic parameters and plasma DCD concentration was assessed with Spearman correlation analysis and Point-biserial correlations. *p < 0.05. DM, diabetes mellitus, CHD, coronary heart disease. (C) Representative images of the magnetic resonance diffusion weighted imaging (MR-DWI) of AIS patients with low plasma DCD concentration (DCD ≤3.33 ng ml−1) or high plasma DCD concentration (DCD > 3.33 ng ml−1). (D) Association between plasma DCD concentration with infarct scale was estimated with Spearman correlation analysis. (E) Association between plasma DCD concentration with delta NIHSS (NIHSS at 7d minus NIHSS at 1d) was estimated with Spearman correlation analysis. (F) Representative images of the chest Computed Tomography (CT) of AIS patients with low plasma DCD concentration (DCD ≤3.39 ng ml−1, median of the cohort) or high plasma DCD concentration (DCD > 3.39 ng ml−1, median of the cohort). (G) Pie charts showing the occurrence of post-stroke pneumonia in AIS patients with low and high plasma DCD concentrations. H) DCD (1 ng ml−1), PBS-migrasomes (PBS-M, 50 μg ml−1) or E. Coli-migrasomes (E. Coli-M, 50 μg ml−1) labeled with Dil (red) were treated to BMDM (15 min). Immunostaining of WGA (green) and DCD (withe) in migrasome-treated BMDM was performed. Experiments were repeated for three times. I,J) BMDM were first pre-stimulated with DCD (1 ng ml−1), PBS-M (50 μg ml−1), or E. Coli-M (50 μg ml−1) for overnight then treated with E. Coli (E. Coli : BMDM = 20:1, 1 h). Phagocytic efficiency of BMDM to GFP expressing E. Coli was assessed with flow cytometry (I) and immunostaining (J). Experiments were repeated three times. **p < 0.01, compared with PBS-treated group by one-way ANOVA (mean ± standard deviation).

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Article Title: Bone Marrow Mesenchymal Stem Cell-Derived Dermcidin-Containing Migrasomes enhance LC3-Associated Phagocytosis of Pulmonary Macrophages and Protect against Post-Stroke Pneumonia.

doi: 10.1002/advs.202206432

Figure Lengend Snippet: Figure 7. DCD is beneficial to AIS recovery and DCD-containing BM-MSC-derived migrasome effectively promotes phagocytosis of macrophages. A– G) Peripheral blood of AIS patients (acute phase, 0–3d after disease onset, n = 16) and healthy controls (HC, n = 8) were collected. (A) Plasma DCD concentration was assessed with ELISA. *p < 0.05, compared with HC by Student’s t-test (mean ± standard deviation). (B) Correlation of clinic parameters and plasma DCD concentration was assessed with Spearman correlation analysis and Point-biserial correlations. *p < 0.05. DM, diabetes mellitus, CHD, coronary heart disease. (C) Representative images of the magnetic resonance diffusion weighted imaging (MR-DWI) of AIS patients with low plasma DCD concentration (DCD ≤3.33 ng ml−1) or high plasma DCD concentration (DCD > 3.33 ng ml−1). (D) Association between plasma DCD concentration with infarct scale was estimated with Spearman correlation analysis. (E) Association between plasma DCD concentration with delta NIHSS (NIHSS at 7d minus NIHSS at 1d) was estimated with Spearman correlation analysis. (F) Representative images of the chest Computed Tomography (CT) of AIS patients with low plasma DCD concentration (DCD ≤3.39 ng ml−1, median of the cohort) or high plasma DCD concentration (DCD > 3.39 ng ml−1, median of the cohort). (G) Pie charts showing the occurrence of post-stroke pneumonia in AIS patients with low and high plasma DCD concentrations. H) DCD (1 ng ml−1), PBS-migrasomes (PBS-M, 50 μg ml−1) or E. Coli-migrasomes (E. Coli-M, 50 μg ml−1) labeled with Dil (red) were treated to BMDM (15 min). Immunostaining of WGA (green) and DCD (withe) in migrasome-treated BMDM was performed. Experiments were repeated for three times. I,J) BMDM were first pre-stimulated with DCD (1 ng ml−1), PBS-M (50 μg ml−1), or E. Coli-M (50 μg ml−1) for overnight then treated with E. Coli (E. Coli : BMDM = 20:1, 1 h). Phagocytic efficiency of BMDM to GFP expressing E. Coli was assessed with flow cytometry (I) and immunostaining (J). Experiments were repeated three times. **p < 0.01, compared with PBS-treated group by one-way ANOVA (mean ± standard deviation).

Article Snippet: Human Monocyte Enrichment and Macrophage Differentiation: Mononucleus cells were isolated from peripheral blood of healthy adults (age = 18–40y) with human peripheral blood monocyte isolation Solution kit (Solarbio, P8680).

Techniques: Derivative Assay, Clinical Proteomics, Concentration Assay, Enzyme-linked Immunosorbent Assay, Standard Deviation, Imaging, Computed Tomography, Labeling, Immunostaining, Expressing, Cytometry